Physicians' Academy for Cardiovascular Education
If HFpEF patients also have atrial fibrillation and/or flutter, they are at increased risk of HF hospitalization or CV death, as shown by a post-hoc analysis of the PARAGON-HF trial.
Keith Ferdinand and Marco Metra talk about how to manage comorbidities, optimize RAASi therapy, and improve the long-term care for patients with heart failure.
Alirocumab reduces MACE irrespective of number of metabolic risk factors, but absolute risk reduction increases with the number of metabolic risk factors, in a post-hoc analysis of ODYSSEY OUTCOMES
In a subgroup analysis of REDUCE-IT, additional treatment with icosapent ethyl resulted in less ischemic events in statin-treated patients with prior MI.
Prof. Konstantinides discusses clinical practice guidelines on anticoagulation for VTE treatment in patients with cancer.
Elevated plasma sLOX-1 levels –observed during acute coronary syndromes (ACS) – predict fatal events beyond both established CV risk factors and the updated GRACE score, in the multicenter SPUM-ACS study.
Despite its increasing popularity, time-restricted eating did not show more benefits in Chinese obese patients after one year than restricting calories alone.
In a follow-up study of the CLEAR Harmony trial, up to 2.5 years of continuous treatment with bempedoic acid was generally well tolerated and stably decreased LDL-c levels in patients with ASCVD and/or heterozygous familial hypercholesterolemia.
A significant reduction in the primary composite endpoint of CV death or worsening HF was reached with dapagliflozin in HF patients with LVEF >40% in the DELIVER phase III trial.
Ahmad Masri and prof. Deepak Bhatt explore the newer cardiac myosin inhibitors that go beyond traditional medical management for the treatment of hypertrophic cardiomyopathy (HCM) at the cellular level. Listen to/watch this animated podcast!
An exploratory analysis showed that apixaban as extended treatment (>90 days) after hospitalization for venous thromboembolism (VTE) is associated with a lower rate of hospitalizations for recurrent VTE versus warfarin as extended treatment.
Prof. Packard shares some thoughts on the potential mechanisms of benefit of icosapent ethyl as seen in the REDUCE-IT trial.
